Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors

NCT01295697 is registered in ClinicalTrials.gov with Enzon Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01295697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01295697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
Lead sponsor
Enzon Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
February 28, 2010
Completion date
January 31, 2013
Enrollment
32 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors